Surveillance of bromocriptine in pregnancy.
Information was collected on the outcome of 1,410 pregnancies in 1,335 women to whom bromocriptine mesylate (Parlodel) had been given, primarily in the early weeks of pregnancy. These Pregnancies resulted in 197 early terminations (14%) (including 25 induced abortions [1.8%) and in 1,213 births (86%). The incidence rate of spontaneous abortions (11.1%), extrauterine pregnancies (0.9%), and minor (2.5%) and major (1.0%) malformations is comparable with that quoted for normal populations, and the incidence of twin pregnancies (1.8%) is slightly but not significantly raised, if correction is made for concomitant therapy with other agents inducing ovulation. The data suggest that the intake of bromocriptine during pregnancy is not associated with an increased risk to the fetus.
D000014:Abnormalities, Drug-Induced / Q000209:etiology; D000022:Abortion, Spontaneous / Q000139:chemically induced; D000293:Adolescent; D000328:Adult; D001724:Birth Weight / Q000187:drug effects; D001971:Bromocriptine / Q000009:adverse effects* / Q000627:therapeutic use; D004700:Endocrine System Diseases / Q000188:drug therapy; D005260:Female; D005333:Fetus / Q000187:drug effects*; D005865:Gestational Age; D006801:Humans; D008431:Maternal-Fetal Exchange; D011247:Pregnancy / Q000187:drug effects*; D011272:Pregnancy, Multiple / Q000187:drug effects; D012306:Risk
D001971:Bromocriptine